R. E. Schopf
YOU?
Author Swipe
View article: Severity of psoriasis and its impact on patient-reported outcomes (PROs): real world evidence with brodalumab 210 mg from the LIBERO study
Severity of psoriasis and its impact on patient-reported outcomes (PROs): real world evidence with brodalumab 210 mg from the LIBERO study Open
LIBERO confirms the benefit of brodalumab on PROs including rapid and complete clearance of skin lesions, quality of life and individual patient benefits - irrespective of their disease severity.
View article: Galenic concept of supersaturation may improve the cutaneous absorption of calcipotriol plus betamethasone dipropionate aerosol foam compared with other topical formulations
Galenic concept of supersaturation may improve the cutaneous absorption of calcipotriol plus betamethasone dipropionate aerosol foam compared with other topical formulations Open
Topical vitamin D3 analogues and corticosteroids are the standard of care for mild-to-moderate psoriasis vulgaris, with >80% of patients managing their condition with topical medications alone.1, 2 Fixed-dose formulations of calcipotriol (…
View article: PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders
PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders Open
Since their introduction in 1999, anti-tumour necrosis factor-α (anti-TNF-α) therapies have been suspected repeatedly to be associated with the occurrence of central nervous system (CNS) demyelinating disorders, including multiple sclerosi…